Pristimerin attenuates spasmolytic polypeptide-expressing metaplasia via p57 (Cdkn1c)-mediated glycolytic reprogramming: A metabolic avenue for gastric cancer prevention

doi:10.3748/wjg.118600

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 32

This Article

(4)

(0)

(10)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Opinion Review

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Aug 28, 2026; 32(32): 118600
Published online Aug 28, 2026. doi: 10.3748/wjg.118600

Open in New Tab Full Size Figure Download Figure

Figure 1 Schematic illustration of the mechanism by which pristimerin inhibits spasmolytic polypeptide-expressing metaplasia. Pristimerin inhibits glycolytic reprogramming and ameliorates spasmolytic polypeptide-expressing metaplasia via p57 pathway-mediated downregulation of hypoxia inducible factor-1α, pyruvate kinase M2, and lactate dehydrogenase A. HIF-1α: Hypoxia inducible factor-1α; PKM2: Pyruvate kinase M2; LDHA: Lactate dehydrogenase A; SPEM: Spasmolytic polypeptide-expressing metaplasia.

Citation: Han JH, Lu KR, Zhang M, Gong GH. Pristimerin attenuates spasmolytic polypeptide-expressing metaplasia via p57 (Cdkn1c)-mediated glycolytic reprogramming: A metabolic avenue for gastric cancer prevention. World J Gastroenterol 2026; 32(32): 118600
URL: https://www.wjgnet.com/1007-9327/full/v32/i32/118600.htm
DOI: https://dx.doi.org/10.3748/wjg.118600

Han JH, Lu KR, Zhang M, Gong GH. Pristimerin attenuates spasmolytic polypeptide-expressing metaplasia via p57 (Cdkn1c)-mediated glycolytic reprogramming: A metabolic avenue for gastric cancer prevention. World J Gastroenterol 2026; 32(32): 118600 [DOI: 10.3748/wjg.118600]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.